Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006449 · ClinicalTrials.gov registry record · Phase 4

Post-Treatment Effects of Naltrexone

A Phase 4 study of Alcoholism, sponsored by Indiana University.

Completed
Registry status
Phase 4
Development phase
160
Enrollment target
1
Study location

NCT00006449 is a Phase 4 study of Alcoholism that has completed, run by Indiana University. The registered enrollment target is 160 participants, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006449, a Phase 4 study of Alcoholism, has completed, sponsored by Indiana University.

COMPLETED
Registry status
Phase 4
Development phase
160 participants
Enrollment target
1
Study location

Study Summary

The aims of this protocol are to compare 3 and 6 months of naltrexone treatment coupled with two psychotherapies that differ in scope and intensity. The effect of these treatments will be assessed with patients who differ in their psychosocial need and resources at their disposal, and in their level of cravings for alcohol.

Conditions Studied

Interventions

  • DRUG naltrexone (Revia)
  • BEHAVIORAL broad spectrum treatment
  • BEHAVIORAL motivational enhancement therapy

Study Locations (1)

Indiana

  • Institute of Psychiatric Research, Indiana University School of Medicine - Indianapolis

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2000-09
Est. Completion 2006-07
Phase Phase 4

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT00006449

The ClinicalTrials.gov registry entry for NCT00006449 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (57% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 3 interventions - of which naltrexone (Revia) is the first listed.

NCT00006449 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT00006449 about?

NCT00006449 is a clinical study titled "Post-Treatment Effects of Naltrexone". The aims of this protocol are to compare 3 and 6 months of naltrexone treatment coupled with two psychotherapies that differ in scope and intensity. The effect of these treatments will be assessed with patients who differ in their psychosocial need and resources at their disposal, and in their level...

What is the current status of trial NCT00006449?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2000-09. Estimated completion is 2006-07.

What conditions does trial NCT00006449 study?

This clinical trial studies the following conditions: Alcoholism.

What interventions are being tested in trial NCT00006449?

The interventions under investigation include: naltrexone (Revia) (DRUG), broad spectrum treatment (BEHAVIORAL), motivational enhancement therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT00006449?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006449 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcoholism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.